The stock of Protalix BioTherapeutics Inc (PLX) has seen a 12.99% increase in the past week, with a 16.00% gain in the past month, and a 20.28% flourish in the past quarter. The volatility ratio for the week is 4.36%, and the volatility levels for the past 30 days are at 5.90% for PLX. The simple moving average for the last 20 days is 4.25% for PLX stock, with a simple moving average of 57.15% for the last 200 days.
Is It Worth Investing in Protalix BioTherapeutics Inc (AMEX: PLX) Right Now?
Protalix BioTherapeutics Inc (AMEX: PLX) has a price-to-earnings ratio of 99.24x that is above its average ratio. Additionally, the 36-month beta value for PLX is -0.02. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for PLX is 72.17M and currently, short sellers hold a 1.36% ratio of that float. The average trading volume of PLX on April 18, 2025 was 685.43K shares.
PLX) stock’s latest price update
The stock price of Protalix BioTherapeutics Inc (AMEX: PLX) has surged by 0.38 when compared to previous closing price of 2.60, but the company has seen a 12.99% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-04-10 that Protalix BioTherapeutics is rated a Strong Buy due to stable income, profitability, and potential from pipeline programs PRX-115 and PRX-119. Elelyso and Elfabrio provide recurring revenue, with increasing royalties expected, and the company has achieved a debt-free status and profitability. PRX-115 shows promise for gout treatment, potentially outperforming KRYSTEXXA, while PRX-119 targets NETs but remains speculative.
Analysts’ Opinion of PLX
Many brokerage firms have already submitted their reports for PLX stocks, with H.C. Wainwright repeating the rating for PLX by listing it as a “Buy.” The predicted price for PLX in the upcoming period, according to H.C. Wainwright is $11 based on the research report published on June 08, 2020 of the previous year 2020.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see PLX reach a price target of $5, previously predicting the price at $4. The rating they have provided for PLX stocks is “Buy” according to the report published on April 17th, 2017.
Rodman & Renshaw gave a rating of “Buy” to PLX, setting the target price at $3.50 in the report published on April 04th of the previous year.
PLX Trading at 6.56% from the 50-Day Moving Average
After a stumble in the market that brought PLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.43% of loss for the given period.
Volatility was left at 5.90%, however, over the last 30 days, the volatility rate increased by 4.36%, as shares surge +10.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.25% lower at present.
During the last 5 trading sessions, PLX rose by +12.99%, which changed the moving average for the period of 200-days by +123.08% in comparison to the 20-day moving average, which settled at $2.50. In addition, Protalix BioTherapeutics Inc saw 38.83% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for PLX
Current profitability levels for the company are sitting at:
- 0.07 for the present operating margin
- 0.54 for the gross margin
The net margin for Protalix BioTherapeutics Inc stands at 0.05. The total capital return value is set at 0.08. Equity return is now at value 7.64, with 3.71 for asset returns.
Based on Protalix BioTherapeutics Inc (PLX), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at 1.57. The debt to equity ratio resting at 0.13. The interest coverage ratio of the stock is 3.69.
Currently, EBITDA for the company is 6.52 million with net debt to EBITDA at -2.18. When we switch over and look at the enterprise to sales, we see a ratio of 3.55. The receivables turnover for the company is 18.36for trailing twelve months and the total asset turnover is 0.73. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.34.
Conclusion
In conclusion, Protalix BioTherapeutics Inc (PLX) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
